New Pain-Measuring device could help people with NF1

NCT ID NCT06507748

Recruiting now Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a device called the AlgometRx Nociometer to see if it can measure pain and other abnormal sensations in people with neurofibromatosis type 1 (NF1). The device uses a small electrode on a finger or toe to send painless signals and a camera to record changes in the pupil of the eye. Researchers hope this will provide a better way to assess pain, especially in those who have trouble describing it. The study involves up to 70 participants aged 1 year and older.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AlgometRx Nociometer device
What this could lead to: If successful, this could provide a new, objective way to measure pain in people with NF1, helping doctors better understand and manage their symptoms.
What could go wrong: This is an early feasibility study with only 70 participants, so results may not apply to everyone. The device is still experimental and may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibromatosis type 1 Pain plexiform neurofibroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS TYPE 1

Contacts and locations

Locations

Children's National Medical Center
RECRUITING

Washington D.C., District of Columbia, 20010, United States
National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.